Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29297336 | 0.82 | TNKS (0.35) | L3MBTL1TNKSNUDT1 | |
| SCHEMBL29297543 | 0.78 | TNKS (0.33) | L3MBTL1TNKSHCRTR2 | |
| SCHEMBL26017168 | 0.78 | L3MBTL1 (0.36) | L3MBTL1TNKSHCRTR2 | |
| SCHEMBL21863368 | 0.77 | L3MBTL1 (0.43) | L3MBTL1TNKSNUDT1HCRTR2 | |
| SCHEMBL17340996 | 0.77 | NUDT1 (0.46) | L3MBTL1TNKSNUDT1 | |
| SCHEMBL9080834 | 0.74 | NUDT1 (0.55) | L3MBTL1TNKSNUDT1 | |
| SCHEMBL6937524 | 0.74 | L3MBTL1 (0.41) | L3MBTL1TNKSNUDT1HCRTR2 | |
| SCHEMBL2179459 | 0.74 | L3MBTL1 (0.41) | L3MBTL1TNKSNUDT1HCRTR2 | |
| SCHEMBL15687846 | 0.73 | L3MBTL1 (0.47) | L3MBTL1TNKSNUDT1HCRTR2 | |
| Bromide SCHEMBL17873904 | 0.73 | L3MBTL1 (0.40) | L3MBTL1TNKSNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | L3MBTL1 1131/4885TNKS 3100/4885ATM 2897/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | L3MBTL1 1316/4885TNKS 4219/4885ATM 4852/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | L3MBTL1 499/4885TNKS 1482/4885ATM 1536/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | L3MBTL1 1131/4885TNKS 3100/4885ATM 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.